



# Ceritinib (Zykadia®)

Lungenkarzinom, nicht-kleinzellig (NSCLC) » ALK+ » ab  
Zweitlinientherapie

Empfehlungen der Fachgesellschaft zum Einsatz neuer Arzneimittel

## **Herausgeber**

DGHO Deutsche Gesellschaft für Hämatologie und  
Medizinische Onkologie e.V.  
Bauhofstr. 12  
10117 Berlin

Geschäftsführender Vorsitzender: Prof. Dr. med. Andreas Hochhaus

Telefon: +49 (0)30 27 87 60 89 - 0

[info@dgho.de](mailto:info@dgho.de)

[www.dgho.de](http://www.dgho.de)

## **Ansprechpartner**

Prof. Dr. med. Bernhard Wörmann  
Medizinischer Leiter

## **Quelle**

[www.onkopedia.com](http://www.onkopedia.com)

Die Empfehlungen der DGHO für die Diagnostik und Therapie hämatologischer und onkologischer Erkrankungen entbinden die verantwortliche Ärztin / den verantwortlichen Arzt nicht davon, notwendige Diagnostik, Indikationen, Kontraindikationen und Dosierungen im Einzelfall zu überprüfen! Die DGHO übernimmt für Empfehlungen keine Gewähr.

# Inhaltsverzeichnis

<b>1 Ceritinib, NSCLC, ALK+, second line .....</b>	<b>2</b>
--	----------

# Ceritinib (Zykadia®)

**Dokument:** Fact Sheet

**Spezifizierung:** Lungenkarzinom, nicht-kleinzellig (NSCLC) » ALK+ » ab Zweitlinientherapie

**Stand:** Juli 2021

## 1 Ceritinib, NSCLC, ALK+, second line

Ceritinib, NSCLC, ALK+, second line				EU Approval 2015																																
Facts				Appraisal																																
<b>Parameter</b>	<b>Results<sup>14</sup></b>		<b>HR<sup>15</sup></b>	<b>p value</b>																																
RR <sup>2</sup>	6.9	vs 39.1				<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 5%;">5</td><td style="width: 5%;">4</td><td style="width: 5%;">3b</td><td style="width: 5%;">3a</td><td style="width: 5%;">2c</td><td style="width: 5%;">2b</td><td style="width: 5%;">2a</td><td style="width: 5%;">1b</td><td style="width: 5%;">1a</td> </tr> <tr> <td style="background-color: #e0e0e0;"></td><td style="background-color: #e0e0e0;"></td><td style="background-color: #e0e0e0;"></td><td style="background-color: #e0e0e0;"></td><td style="background-color: #e0e0e0;"></td><td style="background-color: #e0e0e0;"></td><td style="background-color: #e0e0e0;"></td><td style="background-color: black;"></td><td style="background-color: #e0e0e0;"></td> </tr> </table>										5	4	3b	3a	2c	2b	2a	1b	1a												
5	4	3b	3a	2c	2b	2a	1b	1a																												
PFS <sup>3</sup>	1.6	vs 5.4	0.41	p < 0.001																																
OS <sup>5</sup>	20.1	vs 18.1		n.s. <sup>16</sup>																																
<b>Remarks:</b> 66% of patients in the control arm received Ceritinib at a later stage (crossover/switching).						<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 20%;">1</td><td style="width: 20%;">2</td><td style="width: 20%;">3</td><td style="width: 20%;">4</td><td style="width: 20%;">5</td> </tr> <tr> <td style="background-color: #e0e0e0;"></td><td style="background-color: #e0e0e0;"></td><td style="background-color: #e0e0e0;"></td><td style="background-color: yellow;"></td><td style="background-color: #e0e0e0;"></td> </tr> </table> <p style="font-size: small;"> <span style="color: blue;">■</span> curative    <span style="color: yellow;">■</span> non-curative         </p>										1	2	3	4	5																
1	2	3	4	5																																
<b>Patients</b> ALK+, after Crizotinib and chemotherapy						<b>Additional benefit (G-BA)</b>																														
<b>Trial</b> ASCEND-5, phase 3						<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 20%;"></td><td style="width: 20%; text-align: center;">lower</td><td style="width: 20%; text-align: center;">proven</td><td style="width: 20%; text-align: center;">not quantifiable</td><td style="width: 20%; text-align: center;">not minor</td><td style="width: 20%; text-align: center;">considerable</td><td style="width: 20%; text-align: center;">major</td> </tr> <tr> <td style="background-color: #e0e0e0;">suitable for other systemic treatment<sup>29</sup></td> <td style="background-color: #e0e0e0;"></td><td style="background-color: #e0e0e0;"></td><td style="background-color: #e0e0e0;"></td><td style="background-color: #e0e0e0;"></td><td style="background-color: black;"></td><td style="background-color: #e0e0e0;"></td> </tr> <tr> <td style="background-color: #e0e0e0;">not suitable for other systemic treatment<sup>30</sup></td> <td style="background-color: black;"></td><td style="background-color: #e0e0e0;"></td><td style="background-color: #e0e0e0;"></td><td style="background-color: #e0e0e0;"></td><td style="background-color: #e0e0e0;"></td><td style="background-color: #e0e0e0;"></td> </tr> </table>											lower	proven	not quantifiable	not minor	considerable	major	suitable for other systemic treatment <sup>29</sup>							not suitable for other systemic treatment <sup>30</sup>						
	lower	proven	not quantifiable	not minor	considerable	major																														
suitable for other systemic treatment <sup>29</sup>																																				
not suitable for other systemic treatment <sup>30</sup>																																				
<b>Randomisation</b> 1 : 1																																				
<b>N<sup>1</sup></b> 231																																				
<b>New Therapy</b> Ceritinib																																				
<b>Control</b> Docetaxel or Pemetrexed																																				
<b>Publication</b> DOI:10.1016/S1470-2045(17)30339-X																																				

Legende:

<sup>1</sup> N - number of patients

<sup>2</sup> RR - remission rate, in %

<sup>3</sup> PFS - progression-free survival in months

<sup>5</sup> OS - overall survival in months

<sup>14</sup> results for control, results for new therapy

<sup>15</sup> hazard ratio for new therapy

<sup>16</sup> n. s. not significant

<sup>29</sup> Pemetrexed or Docetaxel

<sup>30</sup> Pemetrexed or Docetaxel